Bavarian Nordic
History
On May 6, 2022, the company was awarded a contract by the Public Health Agency of Canada (PHAC) to provide 500,000 units of Imvamune to the Canadian stockpile.1) The tender announcement described the purchase as being in anticipation of a potential accidental or intentional release of smallpox.2)
Affiliations
Biosecurity
Bavarian Nordic is a funding partner of the Bipartisan Commission on Biodefense.3)
Additionally, the company is a funding partner of the Alliance for Biosecurity,4) and former donor to the Bipartisan Policy Center.5)
Products
Smallpox
Bavarian Nordic manufactures a smallpox vaccine product named Imvamune (Canada), Imvanex (Europe), or Jynneos (United States of America).
1)
Public Services and Procurement Canada. (2022, April 21). Third Generation Smallpox Vaccine (6D024-215700/A). Government of Canada. https://web.archive.org/web/20220620184646/https://buyandsell.gc.ca/procurement-data/tender-notice/PW-PH-893-81160
2)
Osman, L. (2022, May 20). Canada considering smallpox vaccine for monkeypox cases, says Dr. Theresa Tam. CTV News. https://archive.ph/HiTkL
3)
Sponsors / Donors. Bipartisan Commission on Biodefense. Retrieved May 28, 2022, from https://archive.ph/bplYy
4)
Who we are. Alliance for Biosecurity. Retrieved June 20, 2022, from https://archive.ph/FaOGm
5)
2017 Annual Report. (2017). Bipartisan Policy Center. https://web.archive.org/web/20220707070050/https://bipartisanpolicy.org/download/?file=%2Fwp-content%2Fuploads%2F2019%2F07%2FAnnual-Report-2017.pdf